CY1114020T1 - 3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης - Google Patents
3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινηςInfo
- Publication number
- CY1114020T1 CY1114020T1 CY20131100427T CY131100427T CY1114020T1 CY 1114020 T1 CY1114020 T1 CY 1114020T1 CY 20131100427 T CY20131100427 T CY 20131100427T CY 131100427 T CY131100427 T CY 131100427T CY 1114020 T1 CY1114020 T1 CY 1114020T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cyclended
- carbonsamides
- aminocyl
- chemokin
- concentrators
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11805308P | 2008-11-26 | 2008-11-26 | |
| EP09774939.4A EP2370442B9 (en) | 2008-11-26 | 2009-11-20 | 3-Aminocyclopentanecarboxamides as chemokine receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114020T1 true CY1114020T1 (el) | 2016-07-27 |
Family
ID=41693100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100427T CY1114020T1 (el) | 2008-11-26 | 2013-05-29 | 3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης |
Country Status (38)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20146064B (en) * | 2008-11-26 | 2014-03-25 | Pfizer | 3-minocyclopentanecarboxamides as chemokine receptor modulators |
| KR101303963B1 (ko) * | 2011-04-08 | 2013-09-05 | 재단법인 경기과학기술진흥원 | (1ｒ,2ｒ,3ｒ)-3-아미노사이클로펜탄-1,2-디올을 포함하는 항알러지용 조성물 |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| JP2016029038A (ja) * | 2014-07-17 | 2016-03-03 | 参天製薬株式会社 | 加齢黄斑変性の予防または治療剤 |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| TWI830733B (zh) * | 2018-05-11 | 2024-02-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 環戊烷化合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995015973A1 (en) | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| CA2193508A1 (en) | 1994-07-11 | 1996-01-25 | Eugene D. Thorsett | Inhibitors of leukocyte adhesion |
| US5462208A (en) | 1994-08-01 | 1995-10-31 | The Procter & Gamble Company | Two-phase dispensing systems utilizing bellows pumps |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| WO1996031206A2 (en) | 1995-04-07 | 1996-10-10 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of atherosclerosis |
| US5704960A (en) | 1995-12-20 | 1998-01-06 | Corning, Inc. | Method of forming an optical fiber for reduced polarization effects in amplifiers |
| GB9603741D0 (en) | 1996-02-22 | 1996-04-24 | Lin Mei | Treatment of water by electrolysis |
| WO1998002151A2 (en) | 1996-07-12 | 1998-01-22 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
| WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
| EP1017382B1 (en) | 1997-05-29 | 2006-03-01 | Merck & Co., Inc. (a New Jersey corp.) | Biarylalkanoic acids as cell adhesion inhibitors |
| EP1001764A4 (en) | 1997-05-29 | 2005-08-24 | Merck & Co Inc | HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION |
| CA2291708A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
| DE69820614T2 (de) | 1997-05-30 | 2004-09-30 | Celltech Therapeutics Ltd., Slough | Entzündungshemmende tyrosin-derivate |
| US6482849B1 (en) | 1997-06-23 | 2002-11-19 | Tanabe Seiyaku Co., Ltd. | Inhibitors of α4β1 mediated cell adhesion |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| TWI262077B (en) * | 2002-04-29 | 2006-09-21 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2003092586A2 (en) * | 2002-04-29 | 2003-11-13 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| CN102344398B (zh) * | 2003-12-18 | 2015-02-25 | 因赛特公司 | 作为趋化因子受体调控剂的3-环烷基氨基吡咯烷衍生物 |
| US7435830B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| AU2005237500A1 (en) | 2004-04-28 | 2005-11-10 | Merck Sharp & Dohme Corp. | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity |
| CN102382088A (zh) * | 2004-06-28 | 2012-03-21 | 因赛特公司 | 作为趋化因子受体调节剂的3-氨基环戊烷甲酰胺类 |
| AU2005260013A1 (en) * | 2004-06-28 | 2006-01-12 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| CN1976702A (zh) * | 2004-06-28 | 2007-06-06 | 因赛特公司 | 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类 |
| MEP1008A (xx) | 2005-12-21 | 2010-02-10 | Incyte Corp | 3-aminociklopentankarboksamidi kao modulatori receptora hemokina |
| GEP20146064B (en) * | 2008-11-26 | 2014-03-25 | Pfizer | 3-minocyclopentanecarboxamides as chemokine receptor modulators |
-
2009
- 2009-11-20 GE GEAP200912239A patent/GEP20146064B/en unknown
- 2009-11-20 WO PCT/IB2009/055232 patent/WO2010061329A1/en not_active Ceased
- 2009-11-20 BR BRPI0920936-0A patent/BRPI0920936A2/pt not_active Application Discontinuation
- 2009-11-20 RS RS20130260A patent/RS52810B9/sr unknown
- 2009-11-20 DK DK09774939.4T patent/DK2370442T5/da active
- 2009-11-20 PE PE2011001105A patent/PE20110831A1/es active IP Right Grant
- 2009-11-20 CA CA2743030A patent/CA2743030C/en not_active Expired - Fee Related
- 2009-11-20 AU AU2009321221A patent/AU2009321221B2/en not_active Ceased
- 2009-11-20 JP JP2011538083A patent/JP5108153B2/ja active Active
- 2009-11-20 EP EP09774939.4A patent/EP2370442B9/en active Active
- 2009-11-20 RS RS20130260D patent/RS52810B8/sr unknown
- 2009-11-20 KR KR1020117011887A patent/KR101374412B1/ko not_active Expired - Fee Related
- 2009-11-20 NZ NZ592919A patent/NZ592919A/xx not_active IP Right Cessation
- 2009-11-20 HR HRP20130409AT patent/HRP20130409T2/hr unknown
- 2009-11-20 AP AP2011005732A patent/AP3113A/xx active
- 2009-11-20 ES ES09774939T patent/ES2415430T3/es active Active
- 2009-11-20 PL PL09774939T patent/PL2370442T3/pl unknown
- 2009-11-20 PT PT97749394T patent/PT2370442E/pt unknown
- 2009-11-20 SI SI200930601T patent/SI2370442T1/sl unknown
- 2009-11-20 MY MYPI20112377 patent/MY152557A/en unknown
- 2009-11-20 ME MEP-2011-83A patent/ME01144B/me unknown
- 2009-11-20 UA UAA201106571A patent/UA99978C2/uk unknown
- 2009-11-20 CN CN200980147183.7A patent/CN102227429B/zh not_active Expired - Fee Related
- 2009-11-20 MX MX2011005526A patent/MX2011005526A/es active IP Right Grant
- 2009-11-20 EA EA201170721A patent/EA020470B1/ru not_active IP Right Cessation
-
2010
- 2010-06-07 US US12/795,266 patent/US8293903B2/en active Active
-
2011
- 2011-05-05 IL IL212732A patent/IL212732A/en active IP Right Grant
- 2011-05-18 TN TN2011000254A patent/TN2011000254A1/fr unknown
- 2011-05-24 NI NI201100102A patent/NI201100102A/es unknown
- 2011-05-24 CO CO11064157A patent/CO6361921A2/es active IP Right Grant
- 2011-05-25 DO DO2011000154A patent/DOP2011000154A/es unknown
- 2011-05-25 EC EC2011011081A patent/ECSP11011081A/es unknown
- 2011-05-25 CL CL2011001223A patent/CL2011001223A1/es unknown
- 2011-05-26 CU CU2011000121A patent/CU24022B1/es active IP Right Grant
- 2011-05-26 MA MA33895A patent/MA32834B1/fr unknown
- 2011-05-26 SV SV2011003923A patent/SV2011003923A/es unknown
- 2011-05-26 CR CR20110275A patent/CR20110275A/es unknown
- 2011-06-01 ZA ZA2011/04069A patent/ZA201104069B/en unknown
-
2012
- 2012-09-14 US US13/616,375 patent/US8946413B2/en active Active
-
2013
- 2013-05-29 CY CY20131100427T patent/CY1114020T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121792T1 (el) | Ετεροκυκλικη ενωση | |
| CY1119049T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια | |
| CY1120705T1 (el) | Καινοφανεις αναστολεις αποακετυλασων ιστονων | |
| HRP20120323T1 (en) | Diarylhydantoin compounds | |
| EA201000395A1 (ru) | Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида | |
| CY1111671T1 (el) | Ετεροκυκλικη ενωση | |
| CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| UY32730A (es) | Inhibidores de cyp17 | |
| CY1119422T1 (el) | Παραγωγα μπετουλινης | |
| CY1112722T1 (el) | Μυκητοκτονες συνθεσεις | |
| CR11021A (es) | Derivados de quinolina como fungicidas | |
| CY1112467T1 (el) | Παραγωγα 1-θειο-d-γλυκιτολης | |
| CY1115163T1 (el) | Σπειροετεροκυκλικες ν-οξυπιπεριδινες ως ζιζανιοκτονα | |
| EA201201377A1 (ru) | Определенные аминопиридазины, композиции на их основе и способы их использования | |
| EA201490518A1 (ru) | Пирролбензодиазепины | |
| UA113643C2 (xx) | N-цикліламіди як нематоциди | |
| EA201101148A1 (ru) | Новые гербициды | |
| BRPI0821255A2 (pt) | Derivados de espiroindolinona | |
| EA201000396A1 (ru) | Новые фунгициды | |
| EA201000269A1 (ru) | Новые гербициды | |
| EA201170132A1 (ru) | 5-гетероциклилалкил-3-гидрокси-2-фенилциклопент-2-еноны в качестве гербицидов | |
| CY1119121T1 (el) | Αμορφο αλας ενος μακροκυκλικου αναστολεα του hcv | |
| EA201101060A1 (ru) | Новые гербициды | |
| EA200900945A1 (ru) | Новый способ синтеза агомелатина |